Disc Medicine, Inc. (IRON) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseIRON / S&P 14.39% / 15.20% |
LoseIRON / S&P IRON unavailable / 15.00% |
LoseIRON / S&P 47.20% / 50.40% |
| 2026-Q11/3 |
LoseIRON / S&P -19.48% / -4.33% |
LoseIRON / S&P IRON unavailable / 11.30% |
WinIRON / S&P 68.88% / 27.70% |
| 2025-Q42/3 |
WinIRON / S&P 20.17% / 2.65% |
LoseIRON / S&P IRON unavailable / 9.00% |
WinIRON / S&P 50.13% / 13.40% |
| 2025-Q32/3 |
WinIRON / S&P 24.77% / 8.12% |
LoseIRON / S&P IRON unavailable / 4.61% |
WinIRON / S&P 34.42% / 13.45% |
| 2025-Q21/3 |
LoseIRON / S&P 6.69% / 10.94% |
LoseIRON / S&P IRON unavailable / 4.83% |
WinIRON / S&P 21.80% / 10.63% |
| 2025-Q11/3 |
LoseIRON / S&P -21.70% / -4.27% |
LoseIRON / S&P IRON unavailable / 4.98% |
WinIRON / S&P 15.98% / 10.57% |
| 2024-Q42/3 |
WinIRON / S&P 29.02% / 2.41% |
LoseIRON / S&P IRON unavailable / 5.25% |
WinIRON / S&P 14.33% / 6.15% |
| 2024-Q31/3 |
WinIRON / S&P 9.03% / 5.89% |
LoseIRON / S&P IRON unavailable / 5.89% |
LoseIRON / S&P -59.55% / 6.11% |
| 2024-Q20/3 |
LoseIRON / S&P -27.61% / 4.28% |
LoseIRON / S&P IRON unavailable / 5.38% |
LoseIRON / S&P -85.93% / 5.12% |
| 2024-Q10/3 |
LoseIRON / S&P 7.79% / 10.56% |
LoseIRON / S&P IRON unavailable / 5.71% |
LoseIRON / S&P -90.47% / 5.59% |
| 2023-Q41/3 |
WinIRON / S&P 22.95% / 11.69% |
LoseIRON / S&P IRON unavailable / 6.81% |
LoseIRON / S&P -92.24% / 7.78% |
| 2023-Q31/3 |
WinIRON / S&P 5.81% / -3.27% |
LoseIRON / S&P IRON unavailable / 7.52% |
LoseIRON / S&P -87.26% / -5.03% |
| 2023-Q21/3 |
WinIRON / S&P 109.53% / 8.74% |
LoseIRON / S&P IRON unavailable / 9.50% |
LoseIRON / S&P -57.12% / -8.57% |
| 2023-Q10/3 |
LoseIRON / S&P 6.54% / 7.50% |
LoseIRON / S&P IRON unavailable / 10.77% |
LoseIRON / S&P -30.51% / -15.69% |
| 2022-Q40/3 |
LoseIRON / S&P -59.57% / 7.56% |
LoseIRON / S&P IRON unavailable / 11.88% |
LoseIRON / S&P IRON unavailable / -17.99% |
| 2022-Q31/3 |
WinIRON / S&P -2.96% / -4.88% |
LoseIRON / S&P IRON unavailable / 13.47% |
LoseIRON / S&P IRON unavailable / -1.41% |
| 2022-Q21/3 |
WinIRON / S&P 21.58% / -16.10% |
LoseIRON / S&P IRON unavailable / 13.71% |
LoseIRON / S&P IRON unavailable / 11.04% |
| 2022-Q10/3 |
LoseIRON / S&P -52.23% / -4.60% |
LoseIRON / S&P IRON unavailable / 15.97% |
LoseIRON / S&P IRON unavailable / 42.23% |
| 2021-Q40/3 |
LoseIRON / S&P -27.97% / 11.03% |
LoseIRON / S&P IRON unavailable / 15.00% |
LoseIRON / S&P IRON unavailable / 96.40% |
| 2021-Q30/3 |
LoseIRON / S&P -37.56% / 0.58% |
LoseIRON / S&P IRON unavailable / 10.77% |
LoseIRON / S&P IRON unavailable / 69.42% |
| 2021-Q20/3 |
LoseIRON / S&P -52.25% / 8.55% |
LoseIRON / S&P IRON unavailable / 6.58% |
LoseIRON / S&P IRON unavailable / 51.81% |
| 2021-Q11/3 |
WinIRON / S&P 23.18% / 6.17% |
LoseIRON / S&P IRON unavailable / -1.06% |
LoseIRON / S&P IRON unavailable / 7.39% |
| 2020-Q40/3 |
LoseIRON / S&P -1.77% / 12.15% |
LoseIRON / S&P IRON unavailable / -3.72% |
LoseIRON / S&P IRON unavailable / -33.42% |
| 2020-Q30/3 |
LoseIRON / S&P IRON unavailable / 8.93% |
LoseIRON / S&P IRON unavailable / -2.04% |
LoseIRON / S&P IRON unavailable / -27.10% |
| 2020-Q20/3 |
LoseIRON / S&P IRON unavailable / 20.54% |
LoseIRON / S&P IRON unavailable / -0.46% |
LoseIRON / S&P IRON unavailable / -27.11% |
| 2020-Q10/3 |
LoseIRON / S&P IRON unavailable / -19.60% |
LoseIRON / S&P IRON unavailable / 3.47% |
LoseIRON / S&P IRON unavailable / -14.75% |
| 2019-Q40/3 |
LoseIRON / S&P IRON unavailable / 9.07% |
LoseIRON / S&P IRON unavailable / 5.36% |
LoseIRON / S&P IRON unavailable / 2.99% |
| 2019-Q30/3 |
LoseIRON / S&P IRON unavailable / 1.70% |
LoseIRON / S&P IRON unavailable / 5.02% |
LoseIRON / S&P IRON unavailable / 0.21% |
| 2019-Q20/3 |
LoseIRON / S&P IRON unavailable / 4.30% |
LoseIRON / S&P IRON unavailable / 6.64% |
LoseIRON / S&P IRON unavailable / 8.65% |
| 2019-Q10/3 |
LoseIRON / S&P IRON unavailable / 13.65% |
LoseIRON / S&P IRON unavailable / 8.12% |
LoseIRON / S&P IRON unavailable / 14.29% |
| 2018-Q40/3 |
LoseIRON / S&P IRON unavailable / -13.52% |
LoseIRON / S&P IRON unavailable / 9.05% |
LoseIRON / S&P IRON unavailable / 18.23% |
| 2018-Q30/3 |
LoseIRON / S&P IRON unavailable / 7.71% |
LoseIRON / S&P IRON unavailable / 10.21% |
LoseIRON / S&P IRON unavailable / 19.06% |
| 2018-Q20/3 |
LoseIRON / S&P IRON unavailable / 3.43% |
LoseIRON / S&P IRON unavailable / 9.03% |
LoseIRON / S&P IRON unavailable / 14.46% |
| 2018-Q10/3 |
LoseIRON / S&P IRON unavailable / -0.76% |
LoseIRON / S&P IRON unavailable / 7.68% |
LoseIRON / S&P IRON unavailable / 12.46% |
| 2017-Q40/3 |
LoseIRON / S&P IRON unavailable / 6.64% |
LoseIRON / S&P IRON unavailable / 7.03% |
LoseIRON / S&P IRON unavailable / 13.82% |
| 2017-Q30/3 |
LoseIRON / S&P IRON unavailable / 4.48% |
LoseIRON / S&P IRON unavailable / 5.68% |
LoseIRON / S&P IRON unavailable / 17.57% |
| 2017-Q20/3 |
LoseIRON / S&P IRON unavailable / 3.09% |
LoseIRON / S&P IRON unavailable / 4.83% |
LoseIRON / S&P IRON unavailable / 17.74% |
| 2017-Q10/3 |
LoseIRON / S&P IRON unavailable / 6.07% |
LoseIRON / S&P IRON unavailable / 3.67% |
LoseIRON / S&P IRON unavailable / 13.32% |
| 2016-Q40/3 |
LoseIRON / S&P IRON unavailable / 3.82% |
LoseIRON / S&P IRON unavailable / 2.09% |
LoseIRON / S&P IRON unavailable / 7.05% |
| 2016-Q30/3 |
LoseIRON / S&P IRON unavailable / 3.85% |
LoseIRON / S&P IRON unavailable / 0.20% |
LoseIRON / S&P IRON unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IRON total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 38.40% | 20.78% |
| Annualized return | 38.40% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IRON total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -45.83% | 83.14% |
| Annualized return | -11.54% | 12.86% |
10Y · 2020-08-12 to 2026-08-27
| Metric | IRON total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -73.28% | 319.30% |
| Annualized return | -12.37% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |